Harlan Korea Appoints New President - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Harlan Korea Appoints New President

Untitled Document

Kwan Goo Edmond (Ed) Cho, an industry veteran with experience in life sciences and pharmaceuticals, has been selected as the president of Harlan Korea.

As president, Cho will have full profit and loss responsibility and overall accountability for all aspects of the Harlan Contract Research Services (CRS) business stream serving the Korean chemical, agrochemical, and pharmaceutical markets.

Prior to joining Harlan CRS, Cho was director of market access and business development for Zuellig Pharma Korea, an $8 billion subsidiary of the Zuellig Group, providing contract services and clinical reach to multinational companies in more than 15 countries. He also held sales, marketing, and management positions during his 14 years with LG Life Sciences and served in the Special Forces of the Korean Army.

Cho earned a bachelor’s degree and Doctor of Veterinary Medicine degree from Seoul National University.

Source: Harlan



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here